606 related articles for article (PubMed ID: 32134578)
21. Is it possible to predict a disease course prone to macrophage activation syndrome at systemic juvenile idiopathic arthritis diagnosis?
Batu ED; Sener S; Balık Z; Bayındır Y; Cam V; Kasap Cuceoglu M; Uysal O; Aliyev E; Basaran Ö; Bilginer Y; Özen S
Clin Rheumatol; 2024 Jan; 43(1):415-421. PubMed ID: 38012469
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
[TBL] [Abstract][Full Text] [Related]
23. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
[TBL] [Abstract][Full Text] [Related]
24. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.
Ruscitti P; Natoli V; Consolaro A; Caorsi R; Rosina S; Giancane G; Naddei R; Di Cola I; Di Muzio C; Berardicurti O; Iacono D; Pantano I; Rozza G; Rossi S; De Stefano L; Balduzzi S; Vitale A; Caso F; Costa L; Prete M; Navarini L; Iagnocco A; Atzeni F; Guggino G; Perosa F; Cantarini L; Frediani B; Montecucco C; Ciccia F; Cipriani P; Gattorno M; Giacomelli R; Ravelli A
Rheumatology (Oxford); 2022 Oct; 61(10):4124-4129. PubMed ID: 35078234
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
[TBL] [Abstract][Full Text] [Related]
26. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials.
Malattia C; Ruperto N; Pederzoli S; Palmisani E; Pistorio A; Wouters C; Dolezalova P; Flato B; Garay S; Giancane G; Wells C; Douglass W; Brunner HI; De Benedetti F; Ravelli A;
Arthritis Res Ther; 2020 Sep; 22(1):211. PubMed ID: 32912276
[TBL] [Abstract][Full Text] [Related]
28. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
29. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.
Bruck N; Schnabel A; Hedrich CM
Clin Immunol; 2015 Jul; 159(1):72-83. PubMed ID: 25956529
[TBL] [Abstract][Full Text] [Related]
30. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
[TBL] [Abstract][Full Text] [Related]
31. Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease.
Cimaz R; Von Scheven A; Hofer M
Swiss Med Wkly; 2012; 142():w13582. PubMed ID: 22573189
[TBL] [Abstract][Full Text] [Related]
32. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
[TBL] [Abstract][Full Text] [Related]
33. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
Kumar S
Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study.
Sozeri B; Demir F; Barut K; Atalay E; Pac Kisaarslan A; Özdel S; Altuğ Gücenmez Ö; Makay B; Aktay Ayaz N; Haşlak F; Sağ E; Yıldız M; Kaya Akça Ü; Adroviç A; Bilginer Y; Poyrazoğlu H; Ünsal E; Kasapçopur Ö; Özen S
Clin Exp Rheumatol; 2024 Jan; 42(1):194-201. PubMed ID: 37497697
[TBL] [Abstract][Full Text] [Related]
35. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
[TBL] [Abstract][Full Text] [Related]
36. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
[TBL] [Abstract][Full Text] [Related]
37. Systemic JIA: new developments in the understanding of the pathophysiology and therapy.
Vastert SJ; Kuis W; Grom AA
Best Pract Res Clin Rheumatol; 2009 Oct; 23(5):655-64. PubMed ID: 19853830
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
[TBL] [Abstract][Full Text] [Related]
39. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
Hinze CH; Holzinger D; Lainka E; Haas JP; Speth F; Kallinich T; Rieber N; Hufnagel M; Jansson AF; Hedrich C; Winowski H; Berger T; Foeldvari I; Ganser G; Hospach A; Huppertz HI; Mönkemöller K; Neudorf U; Weißbarth-Riedel E; Wittkowski H; Horneff G; Foell D;
Pediatr Rheumatol Online J; 2018 Jan; 16(1):7. PubMed ID: 29357887
[TBL] [Abstract][Full Text] [Related]
40. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
